DK1663236T3 - Kombination, der omfatter n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]-phenyl)-pyridin-3-sulfonamid og et bihosphanat - Google Patents

Kombination, der omfatter n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]-phenyl)-pyridin-3-sulfonamid og et bihosphanat

Info

Publication number
DK1663236T3
DK1663236T3 DK04768282T DK04768282T DK1663236T3 DK 1663236 T3 DK1663236 T3 DK 1663236T3 DK 04768282 T DK04768282 T DK 04768282T DK 04768282 T DK04768282 T DK 04768282T DK 1663236 T3 DK1663236 T3 DK 1663236T3
Authority
DK
Denmark
Prior art keywords
methylpyrazin
bisphosphonate
oxadiazol
sulfonamide
pyridine
Prior art date
Application number
DK04768282T
Other languages
English (en)
Inventor
Neil Gallagher
Jon Owen Curwen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29226541&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1663236(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1663236T3 publication Critical patent/DK1663236T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK04768282T 2003-09-05 2004-09-02 Kombination, der omfatter n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]-phenyl)-pyridin-3-sulfonamid og et bihosphanat DK1663236T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0320806.3A GB0320806D0 (en) 2003-09-05 2003-09-05 Therapeutic treatment
PCT/GB2004/003733 WO2005023264A1 (en) 2003-09-05 2004-09-02 Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an lhrh analogue and/or a bisphosphonate

Publications (1)

Publication Number Publication Date
DK1663236T3 true DK1663236T3 (da) 2009-05-25

Family

ID=29226541

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04768282T DK1663236T3 (da) 2003-09-05 2004-09-02 Kombination, der omfatter n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]-phenyl)-pyridin-3-sulfonamid og et bihosphanat

Country Status (29)

Country Link
US (2) US20060287241A1 (da)
EP (2) EP1663236B1 (da)
JP (1) JP2007504265A (da)
KR (1) KR20060069857A (da)
CN (1) CN1878555A (da)
AR (1) AR045572A1 (da)
AT (1) ATE424206T1 (da)
AU (1) AU2004269956B2 (da)
BR (1) BRPI0413974A (da)
CA (1) CA2537096A1 (da)
CO (1) CO5650255A2 (da)
CY (1) CY1110315T1 (da)
DE (1) DE602004019795D1 (da)
DK (1) DK1663236T3 (da)
ES (1) ES2321620T3 (da)
GB (1) GB0320806D0 (da)
HR (1) HRP20090229T1 (da)
IL (1) IL173817A (da)
IS (1) IS8365A (da)
MX (1) MXPA06002485A (da)
NO (1) NO20061051L (da)
NZ (1) NZ545468A (da)
PL (1) PL1663236T3 (da)
PT (1) PT1663236E (da)
RU (1) RU2398588C2 (da)
SI (1) SI1663236T1 (da)
TW (1) TW200509934A (da)
WO (1) WO2005023264A1 (da)
ZA (1) ZA200601871B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
MX2010003989A (es) 2007-10-12 2010-04-27 Astrazeneca Ab Composicion zibotentan que contiene mannitol y/o celulosa microcristalina.
ES2633453T3 (es) 2008-01-24 2017-09-21 Esperance Pharmaceuticals Constructos de fusión de dominios líticos y métodos de preparación y utilización de los mismos
KR20210090298A (ko) 2012-10-30 2021-07-19 에스퍼란스 파마슈티컬스, 인코포레이티드 항체/약물 컨쥬게이트 및 이의 사용 방법
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9849160B2 (en) * 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524747A (en) * 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US4234571A (en) 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
US4431635A (en) 1979-06-13 1984-02-14 Coy David Howard LH-RH Antagonists
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4547370A (en) 1983-11-29 1985-10-15 The Salk Institute For Biological Studies GnRH Antagonists
US5003011A (en) 1985-04-09 1991-03-26 The Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US4801577A (en) 1987-02-05 1989-01-31 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
US4851385A (en) 1987-07-15 1989-07-25 Indiana University Foundation LHRH antagonist analogs having low histamine-release activity
US4935491A (en) 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5300492A (en) 1988-02-10 1994-04-05 Tap Pharmaceuticals LHRH analogs
US4992421A (en) 1988-04-19 1991-02-12 Abbott Laboratories Luteinizing hormone releasing hormone antagonist
US5296468A (en) 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
US5668254A (en) 1990-05-11 1997-09-16 Romano Deghenghi D-2-alkyl-tryptophan and peptides containing same
US5171635A (en) 1990-10-10 1992-12-15 E. I. Du Pont De Nemours And Company Composite wire construction
US5371070A (en) 1992-11-09 1994-12-06 The Salk Institute For Biological Studies Bicyclic GnRH antagonists and a method for regulating the secretion of gonadotropins
US5413990A (en) 1993-08-06 1995-05-09 Tap Pharmaceuticals Inc. N-terminus modified analogs of LHRH
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
CN1063446C (zh) 1995-10-19 2001-03-21 武田药品工业株式会社 作为促性腺激素释放激素拮抗剂的噻吩并吡啶衍生物
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
EP0839525B1 (en) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
US20020055457A1 (en) * 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
SE0100568D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
SE0100566D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
SE0100567D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
US20030092757A1 (en) * 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
RU2297229C2 (ru) * 2001-05-02 2007-04-20 Новартис Аг Фармацевтическое применение бисфосфонатов
SE0101692D0 (sv) 2001-05-14 2001-05-14 Astrazeneca Ab Compounds
JP2003137814A (ja) * 2001-08-10 2003-05-14 Takeda Chem Ind Ltd ＧｎＲＨアゴニストの併用剤
US7098305B2 (en) 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
DE10155076A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
GB0223367D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment

Also Published As

Publication number Publication date
AU2004269956B2 (en) 2008-04-17
US20100004181A1 (en) 2010-01-07
DE602004019795D1 (de) 2009-04-16
CY1110315T1 (el) 2015-01-14
IL173817A (en) 2011-03-31
JP2007504265A (ja) 2007-03-01
KR20060069857A (ko) 2006-06-22
HRP20090229T1 (en) 2009-05-31
CO5650255A2 (es) 2006-06-30
NZ545468A (en) 2009-03-31
IL173817A0 (en) 2006-07-05
CN1878555A (zh) 2006-12-13
ZA200601871B (en) 2007-05-30
EP2018865A3 (en) 2009-11-18
TW200509934A (en) 2005-03-16
GB0320806D0 (en) 2003-10-08
ATE424206T1 (de) 2009-03-15
RU2398588C2 (ru) 2010-09-10
BRPI0413974A (pt) 2006-10-31
RU2006110736A (ru) 2007-10-10
ES2321620T3 (es) 2009-06-09
MXPA06002485A (es) 2006-06-20
AR045572A1 (es) 2005-11-02
AU2004269956A1 (en) 2005-03-17
EP1663236A1 (en) 2006-06-07
EP2018865A2 (en) 2009-01-28
SI1663236T1 (sl) 2009-06-30
CA2537096A1 (en) 2005-03-17
EP1663236B1 (en) 2009-03-04
NO20061051L (no) 2006-04-03
PL1663236T3 (pl) 2009-07-31
WO2005023264A1 (en) 2005-03-17
US20060287241A1 (en) 2006-12-21
PT1663236E (pt) 2009-04-24
IS8365A (is) 2006-03-20
HK1090294A1 (en) 2006-12-22

Similar Documents

Publication Publication Date Title
DK1663236T3 (da) Kombination, der omfatter n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]-phenyl)-pyridin-3-sulfonamid og et bihosphanat
PT1482798E (pt) Misturas fungicidas a base de protioconazol e de trifloxystrobina
ATE308544T1 (de) N-substituiete heteroaryloxy-aryl-spiro- pyrimidine-2,4,6-trion metalloproteinase inhibitoren
ATE363463T1 (de) 2-(2,6-dichlorphenyl)-diarylimidazole
DE502004002833D1 (de) Alkoxysilanterminierte prepolymere
DE50306248D1 (de) Zielgerät für einen Verriegelungsnagel
DE50303339D1 (de) Zielgerät für einen Verriegelungsnagel
ATE304015T1 (de) Triaryl-oxy-aryl-spiro-pyrimidin-2, 4, 6-trion metalloproteinase inhibitoren
DE50301281D1 (de) Zielgerät für einen Verriegelungsnagel
ATE395077T1 (de) Hundeimpfstoffe gegen bordetella bronchiseptica
DE60318991D1 (de) Verteilter fehlerbeständiger gemeinsam benutzter speicher
FR2838302B1 (fr) Maillot debain a zones elastiques
FI20031014A0 (fi) Siirtolaite
DE50302914D1 (de) Polymerisierbare mischungen
DE50205472D1 (de) Piezoelektrischer antrieb
DK1443821T3 (da) Svampedræbende sammensætning baseret på et pyridylmethylbenzamid- og et valinamid-derivat
IS2704B (is) Notkun N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-[1,3,4-oxadíasól-2-ýl]fenýl)pýridín-3-súlfónamíðs við meðhöndlun á krabbameini
IL182854A0 (en) A combination of n - (3 - methoxy - 5 - methylpyrazin - 2 - yl) - 2 - (4 - [1,3,4 - oxadiazol - 2 - yl] phenyl) pyridine - 3 - sulphonamide and an anti - mitotic agent for the treatment of cancer
ITRM20020504A1 (it) Compattatore essiccatore a gabbia a doppio flusso e
DE60335104D1 (de) Amidoacetonitril-verbindungen gegen parasiten
SE0202132L (sv) En jordbearbetningsenhet
PT1475060E (pt) Juncao articulada para uma cinta pos-operatoria
DK1656021T3 (da) Lagerstabile herbicide blandinger med metazachlor
IS7581A (is) Lyfjasamsetning
EP1692125A4 (en) IRCINIASTATINES A AND B